{"page":{"totalFilteredElements":90},"studies":[{"active":true,"description":"Prävention von frühen Darmkrebserkrankungen - PEARL","eudractNumber":null,"id":11520,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05541601","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2022-10-10T09:00:45+02:00","shortTitle":"PEARL","therapeutical":false,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Prospektive Studie zum multiplen Myelom: eine Anwendungsbeurteilung","eudractNumber":null,"id":2692,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT01838512","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2023-12-21T09:09:43+01:00","shortTitle":"PREAMBLE CA204-008","therapeutical":false,"therapyLines":[]},{"active":true,"description":"PRESS -PAR: Early detection and PREvention of Symptomatic\npostSurgical hypoPARathyroidism\nafter thyroid surgery","eudractNumber":null,"id":9865,"indications":[{"id":"nen","name":"Bösartige Tumoren der Nebenniere"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2024-07-15T09:25:46+02:00","shortTitle":"PRESSPAR","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Evaluation der DIGA consilium care bei Patientinnen mit Her 2 positiven Brustkrebs während einer Chemotherapie in Kombination mit einer Her 2 zielgerichteten Antikörper Therapie","eudractNumber":null,"id":8562,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05425550","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2023-06-01T09:40:37+02:00","shortTitle":"PRO2","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"
PROstate CAncer Real World Evidence Registry: Registerstudie zur Erfassung des Therapie- und Krankheitsverlaufs bei Patienten mit rezidiviertem und metastasiertem Prostatakrebs

DRKS00033411
","eudractNumber":null,"id":10394,"indications":[{"id":"pro","name":"Prostatakrebs"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2024-11-07T12:57:01+01:00","shortTitle":"PROCARE","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Real world experience of patients with metastatic castration resistant prostate Cancer treated with Olaparib+Abiraterone","eudractNumber":null,"id":9252,"indications":[{"id":"pro","name":"Prostatakrebs"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2024-02-01T13:58:55+01:00","shortTitle":"PROCEED","therapeutical":false,"therapyLines":[]},{"active":true,"description":"

Prophylaktische\nWirkung eines retromuskulären Netzes während Ileostomarückverlagerung auf die\nInzidenz von Narbenhernien – eine multizentrische randomisierte Patienten- und\nBeobachter-verblindete Studie

\n\n(P.E.L.I.O.N.\nTrial)
DRKS00027921
","eudractNumber":null,"id":9368,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2024-03-04T12:15:13+01:00","shortTitle":"Pelion","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"

Etablierung kontinuierlicher perioperativer\nBlutglucosemessungen zur Detektion metabolischer Veränderungen bei Patienten in\nder Viszeralchirurgie: Machbarkeits- und Etablierungsstudie

","eudractNumber":null,"id":11032,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2025-06-15T13:14:09+02:00","shortTitle":"PeriOPGlukose","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Anwendung von Privigen® bei sekundärer Immunschwäche: Eine multizentrische Beobachtungsstudie (IgPro10_5008)

NIS-Nr.:742
","eudractNumber":null,"id":9261,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2023-02-15T13:25:54+01:00","shortTitle":"Privigen","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"

NAFLD Kohorte Dr. Rau - Prospektive Verlaufsbeobachtung bei Patienten mit Nicht-alkoholischer Fettlebererkrankung\n(Fettleberkohorte)

","eudractNumber":null,"id":2264,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2012-10-01T09:59:40+02:00","shortTitle":"Prospektive Verlaufsbeobachtung bei Patienten mit Nicht-alkoholischer Fettlebererkrankung (Fettleberkohorte)","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]}]}